+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Cancer Vaccines Market by Technology, Treatment Method, Application - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 198 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6010630
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Cancer Vaccines Market grew from USD 17.90 billion in 2023 to USD 20.56 billion in 2024. It is expected to continue growing at a CAGR of 15.37%, reaching USD 48.71 billion by 2030.

The scope of cancer vaccines encompasses prophylactic and therapeutic vaccines designed to prevent or treat various types of cancer by stimulating the body's immune system. The necessity for these vaccines lies in their potential to provide more personalized, targeted cancer treatments with fewer side effects compared to conventional therapies. They can be used in several applications, such as preventing virus-induced cancers like cervical cancer, boosting post-surgical immune response, or targeting specific cancer antigens. The end-use scope involves hospitals, cancer treatment centers, and research institutions that focus on innovative therapeutic interventions. Market insights reveal that the growth of the cancer vaccine sector is driven by advances in biotechnology, increasing incidence of cancer, and rising funding for cancer research. Strategic partnerships between pharmaceutical companies and research organizations further propel market expansion. Cutting-edge developments in immunotherapy and personalized medicine offer new opportunities, particularly in the development of mRNA-based vaccines and neoantigen vaccines. Companies should focus on collaborations and investments in these areas to harness growth potential.

However, market growth is hindered by several challenging factors such as high costs associated with vaccine development, complex regulatory pathways, limited awareness in developing regions, and potential adverse effects. The competitive landscape is further strained by the requirement of technical expertise and lengthy clinical approval processes. Addressing these challenges could involve increasing investment in R&D, ensuring more streamlined regulatory approvals, and enhancing public-private partnerships to boost awareness and accessibility. Areas of innovation include exploring novel antigens, advancing personalized cancer vaccine platforms, and integrating artificial intelligence in vaccine development processes. Business growth could benefit from diversifying product pipelines and adopting adaptive strategies that align with evolving scientific and technological trends. The nature of the market is dynamic, necessitating agility from industry players to adapt to rapid advancements in science and technology, thereby ensuring sustained growth and competitive advantage in the burgeoning field of cancer vaccines.

Understanding Market Dynamics in the Cancer Vaccines Market

The Cancer Vaccines Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increase in number of cancer patients along with growing geriatric population
    • Surge in patient awareness towards cancer therapy
    • Increase in prevalence of human papilloma virus (HPV) infections
  • Market Restraints
    • High cost for developing cancer vaccines
  • Market Opportunities
    • Increase in investments and government funding in development of cancer vaccines
    • Technological developments in cancer vaccines
  • Market Challenges
    • Longer time span required for manufacturing a single vaccine

Exploring Porter’s Five Forces for the Cancer Vaccines Market

Porter’s Five Forces framework further strengthens the insights of the Cancer Vaccines Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Cancer Vaccines Market

External macro-environmental factors deeply influence the performance of the Cancer Vaccines Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Cancer Vaccines Market

The Cancer Vaccines Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Cancer Vaccines Market

The Cancer Vaccines Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Cancer Vaccines Market

The Cancer Vaccines Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Vaccines Market, highlighting leading vendors and their innovative profiles. These include Advaxis Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Celldex Therapeutics, Dynavax Technologies, GSK PLC, Helsinn Healthcare SA, Johnson & Johnson, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi SA, Sanpower Group Co., Ltd., and Sun Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Cancer Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Technology
    • Antigen
    • Dendritic Cells
    • Recombinant Cancer Vaccines
    • Viral Vector & DNA Cancer Vaccines
    • Whole-cell Cancer Vaccines
  • Treatment Method
    • Preventive Vaccine
    • Therapeutic Vaccine
  • Application
    • Cervical Cancer
    • Prostate Cancer
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increase in number of cancer patients along with growing geriatric population
5.1.1.2. Surge in patient awareness towards cancer therapy
5.1.1.3. Increase in prevalence of human papilloma virus (HPV) infections
5.1.2. Restraints
5.1.2.1. High cost for developing cancer vaccines
5.1.3. Opportunities
5.1.3.1. Increase in investments and government funding in development of cancer vaccines
5.1.3.2. Technological developments in cancer vaccines
5.1.4. Challenges
5.1.4.1. Longer time span required for manufacturing a single vaccine
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Cancer Vaccines Market, by Technology
6.1. Introduction
6.2. Antigen
6.3. Dendritic Cells
6.4. Recombinant Cancer Vaccines
6.5. Viral Vector & DNA Cancer Vaccines
6.6. Whole-cell Cancer Vaccines
7. Cancer Vaccines Market, by Treatment Method
7.1. Introduction
7.2. Preventive Vaccine
7.3. Therapeutic Vaccine
8. Cancer Vaccines Market, by Application
8.1. Introduction
8.2. Cervical Cancer
8.3. Prostate Cancer
9. Americas Cancer Vaccines Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Cancer Vaccines Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Cancer Vaccines Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.4. Strategy Analysis & Recommendation
LIST OF FIGURES
FIGURE 1. CANCER VACCINES MARKET RESEARCH PROCESS
FIGURE 2. CANCER VACCINES MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CANCER VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 7. GLOBAL CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2023 VS 2030 (%)
FIGURE 9. GLOBAL CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL CANCER VACCINES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL CANCER VACCINES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS CANCER VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS CANCER VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES CANCER VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES CANCER VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. CANCER VACCINES MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. CANCER VACCINES MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
TABLE 1. CANCER VACCINES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CANCER VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. CANCER VACCINES MARKET DYNAMICS
TABLE 7. GLOBAL CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CANCER VACCINES MARKET SIZE, BY ANTIGEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CANCER VACCINES MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CANCER VACCINES MARKET SIZE, BY RECOMBINANT CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CANCER VACCINES MARKET SIZE, BY VIRAL VECTOR & DNA CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CANCER VACCINES MARKET SIZE, BY WHOLE-CELL CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CANCER VACCINES MARKET SIZE, BY PREVENTIVE VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CANCER VACCINES MARKET SIZE, BY THERAPEUTIC VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CANCER VACCINES MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CANCER VACCINES MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 23. ARGENTINA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 27. BRAZIL CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 28. BRAZIL CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 29. CANADA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 30. CANADA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 31. CANADA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 32. MEXICO CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 33. MEXICO CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 34. MEXICO CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES CANCER VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 42. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 43. AUSTRALIA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 44. AUSTRALIA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 45. AUSTRALIA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 46. CHINA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 47. CHINA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 48. CHINA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 49. INDIA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 50. INDIA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 51. INDIA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 52. INDONESIA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 53. INDONESIA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 54. INDONESIA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 55. JAPAN CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 56. JAPAN CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 57. JAPAN CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 58. MALAYSIA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 59. MALAYSIA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 60. MALAYSIA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 61. PHILIPPINES CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 62. PHILIPPINES CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 63. PHILIPPINES CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 64. SINGAPORE CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 65. SINGAPORE CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 66. SINGAPORE CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 67. SOUTH KOREA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 68. SOUTH KOREA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 69. SOUTH KOREA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 70. TAIWAN CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 71. TAIWAN CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 72. TAIWAN CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 73. THAILAND CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 74. THAILAND CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 75. THAILAND CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 76. VIETNAM CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 77. VIETNAM CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 78. VIETNAM CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 83. DENMARK CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 84. DENMARK CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 85. DENMARK CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 86. EGYPT CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 87. EGYPT CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 88. EGYPT CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 89. FINLAND CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 90. FINLAND CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 91. FINLAND CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 92. FRANCE CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 93. FRANCE CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 94. FRANCE CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 95. GERMANY CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 96. GERMANY CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 97. GERMANY CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 98. ISRAEL CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 99. ISRAEL CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 100. ISRAEL CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 101. ITALY CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 102. ITALY CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 103. ITALY CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 104. NETHERLANDS CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 105. NETHERLANDS CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 106. NETHERLANDS CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 108. NIGERIA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 109. NIGERIA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 110. NORWAY CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 111. NORWAY CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 112. NORWAY CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 113. POLAND CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 114. POLAND CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 115. POLAND CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 116. QATAR CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 117. QATAR CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 118. QATAR CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 124. SAUDI ARABIA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 126. SOUTH AFRICA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 127. SOUTH AFRICA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 128. SPAIN CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 129. SPAIN CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 130. SPAIN CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 132. SWEDEN CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 133. SWEDEN CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 135. SWITZERLAND CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 136. SWITZERLAND CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 137. TURKEY CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 138. TURKEY CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 139. TURKEY CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 146. CANCER VACCINES MARKET SHARE, BY KEY PLAYER, 2023
TABLE 147. CANCER VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Cancer Vaccines market, which are profiled in this report, include:
  • Advaxis Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Celldex Therapeutics
  • Dynavax Technologies
  • GSK PLC
  • Helsinn Healthcare SA
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi SA
  • Sanpower Group Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information